Akari Therapeutics, Plc (AKTX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Akari Therapeutics, Plc (AKTX) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.24 and trailing twelve-month earnings per share of $-48262.47.
Compared to the Healthcare sector median P/E of 23.7x, AKTX trades at a 100% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, AKTX trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AKTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See AKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AKTX vs AGIO
See how AKTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AKTX stock overvalued or undervalued?
AKTX current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
How does AKTX's valuation compare to peers?
Akari Therapeutics, Plc P/E of -0.0x compares to sector median of 23.7x. Sector comparison provides relative valuation context.
What is AKTX's PEG ratio?
AKTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.